Deltaretrovirus infections, particularly those caused by Human T-Cell Lymphotropic Virus (HTLV), have gained attention in recent years due to evolving insights into their pathogenesis and potential therapeutic approaches. HTLV-1 has been associated not only with hematological malignancies and neurological disorders but also with inflammatory conditions such as uveitis and arthritis. Recent research has uncovered the complex interplay between the virus and the host immune system, shedding light on the mechanisms leading to disease progression. Therapeutic strategies for deltaretrovirus infections are challenging due to the lack of specific antiviral drugs. Clinical trials exploring the effectiveness of various antiretroviral agents and immunomodulatory approaches are ongoing. Additionally, efforts are directed towards understanding the viral reservoirs and developing targeted therapies to eliminate persistent infections. The development of preventive vaccines remains a crucial area of investigation to curb the transmission of HTLV and mitigate the associated health burdens.